Beta-blocker use not linked to reduced mortality after AMI
Tatendashe B. Dondo, from the University of Leeds in the United Kingdom, and colleagues examined the correlation between β-blocker use and mortality among 179,810 survivors of hospitalization with AMI without heart failure or LVSD (91,895 patients with ST-segment elevation myocardial infarction [STEMI] and 87,915 patients with non-STEMI).
The researchers found that 96.4 and 93.2 percent of patients with STEMI and non-STEMI received β-blockers, respectively. There were deaths in 5.2 percent of the entire cohort. Patients receiving β-blockers had lower unadjusted one-year mortality than non-users (4.9 versus 11.2 percent; P < 0.001). No significant difference was seen in mortality for those with and without β-blocker use after weighting and adjustment (average treatment effect [ATE] coefficient, 0.07; P = 0.827). Similar findings were seen for STEMI (ATE coefficient, 0.30; P = 0.637) and non-STEMI (ATE coefficient, −0.07; P = 0.819).
"Among survivors of hospitalization with AMI who did not have heart failure or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to one year," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Editorial (subscription or payment may be required)
Copyright © 2017 HealthDay. All rights reserved.